Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. 

 Financial ResultsNet cash used in operating activities for the Year

$3.9 millionCash position at the end of the Year

$5.1 millionReported loss

$4.1 million 

Operational HighlightsCAVATAK™ Phase II CALM Melanoma Clinical Trial (USA) Highlights include:

  • CAVATAK™ presented at the American Society of Clinical Oncologists conference in June 2013 and the World Melanoma Congress in July 2013 to a global oncology audience.
  • Key milestone achieved with enrolment of the 35th patient. Independent Data Monitoring Committee reported that CAVATAK™ had met safety and tolerability criteria.
  • Patient enrolment now at 10 prestigious US cancer clinics, with acceleration since early 2013. Aiming for full recruitment by the end of the calendar year.
  • 23 patients have reached assessment point against the trial's primary endpoint of immune related Progression Free Survival (irPFS) at 6 months. Interim results very promising with 8 of 23 patients having achieved the primary endpoint. Trial target is 10 of 54 evaluable patients achieving primary endpoint.
  • 2 complete and 6 partial tumour responses from 30 assessable patients. Anti-cancer activity demonstrated in non-injected (metastatic or secondary) as well as the injected tumours.
  • CAVATAK™ Phase I studies completed (Australia)

  • Intravenously administered CAVATAK™ well tolerated in late stage cancer patients.
  • Some evidence of tumour stabilization in intravenous study after only a single dose.
  • Sound basis for a multi-dose intravenous Phase 1 / 2 trial (our STORM study).
  • CAVATAK™ Preclinical studies completed (A
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
    (Date:8/28/2014)... 2014  Stryker Orthopaedics, the Official Joint Replacement Products of ... of joint health to golf fans at the next stop ... Bank Championship. The company,s fan destination – "The Stryker Mobility ... 9" at the TPC Boston in Norton, MA ... At the Deutsche Bank Championship, Stryker will be ...
    (Date:8/28/2014)... OAKS, Calif. , Aug. 28, 2014 ... submission of a Biologics License Application (BLA) to the ... approval for the treatment of high cholesterol. Evolocumab is ... convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces ... or "bad" cholesterol, from the blood. 1 ...
    Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
    ... Oct. 31 2011 VolitionRX Limited (VNRX.OB) ("Volition" or the ... tests, publishes the following letter to its shareholders from Cameron ... speed at which our company has been growing and the ... would like to review the past year and look forward ...
    ... Japan, Oct. 31, 2011 Menicon Holdings BV and ... Thea, a France-based independent ophthalmic group, announced on October ... partner to market the SOLO-care (R) contact lens solutions ... and Canada. The agreement will enable Menicon ...
    Cached Medicine Technology:VolitionRX Limited Issues Update Letter to Shareholders 2VolitionRX Limited Issues Update Letter to Shareholders 3VolitionRX Limited Issues Update Letter to Shareholders 4VolitionRX Limited Issues Update Letter to Shareholders 5Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2
    (Date:8/28/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for surgical ... Driven by the need for replacement of existing installations ... geographies, the market is expected to grow to $631.9 ... 8.5% from 2013 through 2018. , While revenue generation ...
    (Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
    (Date:8/28/2014)... August 28, 2014 Clarity PSO ... been re-certified as a federal Patient Safety Organization (PSO) ... Agency for Healthcare Research and Quality (AHRQ). Clarity PSO ... expertise and services following the true intentions of the ... , ”We are proud and eager to continue our ...
    (Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... business sector recently launched a “Video” section located ... and general information on various cannabis companies in ... can find an assortment of news clips, interviews, ... and announcements. A portion of the videos can ...
    (Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider ... recipes to help clients and online readers send out ... Chef Han Ashley developed variations of Roasted Veggie ... , The PreDiabetes Centers Roasted Veggie Pizza recipe is ... and features a cheese substitute–ideal for people who are ...
    Breaking Medicine News(10 mins):Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3
    ... fall asleep swiftly if your hands and feet are warmer ... hot baths and// sleeping pills have all been put forward ... nothing beats the dilation of blood vessels in the hands ... ,Dr Kurt Krauchi and his team at the ...
    ... insomniacs would fare better if they kept the bed for ... A Canadian study found that taking sleeping pills worked in ... a long period. , Insomnia is defined as trouble ... early in the morning without being able to get back ...
    ... linked high levels of blood fats called triglycerides to ... physicians to pay closer attention to triglyceride levels.// More ... treatments to modify this stroke risk factor could further ... that drugs that lower blood fats can also prevent ...
    ... breast cancer patients feel better, but it won't help them ... their medical treatment lived an average// of 18 months longer. ... any longer than the 77 who got only medical treatmen. ... and emotional distress -- especially if the levels were high ...
    ... and other vascular diseases are the leading causes ... in depiction of stenotic, occlusive, aneurismal, inflammatory or ... (DSA) are used to depict vascular lesions with ... material.// It is the gold standard with a ...
    ... a common liver disease may be caused by the production ... to affect around one in four people in developed countries. ... currently untreatable, and one in ten sufferers go on to ... risk that cancer will develop in the organ.The damage caused ...
    Cached Medicine News:Health News:Cure for sleepless nights 2Health News:Magnetic resonance angiography in clinical medicine 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: